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Abstract: Ranolazine (Ran), an anti-anginal drug, is a late Na+ channel 
current blocker that is also believed to attenuate fatty acid oxidation and 
mitochondrial respiratory complex I activity, especially during ischemia. In 
this study, we investigated if Ran's protective effect against cardiac 
ischemia/reperfusion (IR) injury is mediated at the mitochondrial level and 
specifically if respiratory complex I (NADH oxidoreductase) function is 
protected. We treated isolated and perfused guinea pig hearts with Ran just 
before 30 min ischemia and then isolated cardiac mitochondria at the end of 
30 min ischemia and/or 30 min ischemia followed by 10 min reperfusion. We 
utilized spectrophotometric and histochemical techniques to assay complex I 
activity, western blot analysis for complex I subunit NDUFA9, electron 
paramagnetic resonance for activity of complex I Fe-S clusters, ELISA for 
determination of protein acetylation, native gel histochemical staining for 
respiratory supercomplex assemblies, and high pressure liquid 
chromatography for cardiolipin integrity; cardiac function was measured 
during IR. Ran treated hearts showed higher complex I activity and greater 
detectable complex I protein levels compared to untreated IR hearts. Ran 
treatment also led to more normalized electron transfer via Fe-S centers, 
supercomplex assembly and cardiolipin integrity. These improvements in 
complex I structure and function with Ran were associated with improved 
cardiac function after IR. However, these protective effects of Ran are not 
mediated by a direct action on mitochondria, but rather indirectly via cytosolic 
mechanisms that lead to less oxidation and better structural integrity of 
complex I. 
Keywords: Complex I, mitochondria, IR injury, ranolazine, EPR, heart 
1. Introduction 
It is now evident that mitochondria play an important role in 
mediating both protection and damage during cardiac ischemia 
reperfusion (IR) injury. An important target for protection is 
mitochondrial complex I (NADH-Ubiquinone oxidoreductase) [1, 2]. 
Complex I is a large, multi-subunit, integral membrane protein highly 
susceptible to functional and structural damage during IR injury [3, 4]. 
Complex I is bound by cardiolipin, a highly unsaturated fatty acid lipid 
in the inner mitochondrial membrane (IMM). Cardiolipin is essential for 
maintaining functional and structural integrity of the respiratory 
complexes and to assure efficient transfer of electrons (e-) within 
subunits of the complexes and between the complexes [5]. The 
transfer of e- via sequential oxidation-reduction of Fe in the seven Fe-S 
clusters of complex I exemplifies this critical role of cardiolipin [6, 7]. 
Because cardiolipin is susceptible to oxidative attack by reactive O2 
species (ROS) [8, 9] leading to peroxidation and carbon chain 
breakdown [10], the assemblies of respiratory complexes are also 
dependent on integrity of cardiolipin. 
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Ranolazine (Ran) is a clinically used drug known to reduce 
cardiac dysrhythmias [11-15] and tissue damage after IR [16]. During 
IR injury, Na+ can slowly enter myocytes during phase 3 of the action 
potential to initiate dysrhythmias [11]; thus as a late Na+ channel 
current blocker [13], Ran is believed to protect hearts by reducing the 
incidence of dysrhythmias during IR injury. However, since Ran 
prevents intracellular Na+ loading, particularly during IR, it could also 
decrease cytosolic Ca2+ overload via Na+/Ca2+ exchange (NCE) and 
consequently decrease mitochondrial Ca2+ (m[Ca2+]) overload [17]; 
m[Ca2+] overload is thought to cause increased production of ROS and 
to trigger cell apoptosis by release of cytochrome c. These events may 
underlie, at least in part, the protection afforded by Ran against 
cardiac tissue damage during IR. 
Indeed, in a recent isolated heart study of IR injury [18] we 
found that Ran treatment just before ischemia reduced cytosolic and 
m[Ca2+] loading and ROS emission and, in isolated mitochondria, 
reduced cytochrome c release and slightly delayed opening of the 
mitochondrial permeability transition pore (mPTP) during cardiac IR 
injury. Other reports suggest that Ran exerts a cardioprotective effect 
by switching substrate utilization from fatty acids to glucose 
metabolism [16, 19, 20], which reduces mitochondrial O2 demand and 
that Ran partially blocks respiratory complex I activity [21]. Although 
these prior studies give insight into Ran's mode of cardioprotection, 
there is no direct evidence that Ran actually attenuates mitochondrial 
dysfunction during IR injury 
Given the role of complex I in generating ROS during IR [4, 22] 
and the crucial role of cardiolipin [4, 10, 22, 23] in promoting efficient 
e- transfer, we sought first to assess changes in many markers of 
complex I function during IR injury and second to determine if there 
were any direct beneficial biophysical and biochemical effects of Ran 
on complex I during IR. Because it was unclear if Ran directly targets 
mitochondria to protect against IR injury, we hypothesized that Ran, 
when present during ischemia, preserves cardiolipin and supercomplex 
assembly integrity, and especially complex I activity, by its direct 
effect to reduce ROS emission and oxidation of mitochondrial 
components as a primary mechanism to protect against cardiac IR 
injury; alternatively, Ran has indirect effects to restore complex I 
function. 
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2. Materials and Methods 
2.1. Isolated heart preparation and functional 
assessment 
The Institutional Animal Care and Usage Committee of the 
Medical College of Wisconsin approved all animal studies. Guinea pig 
hearts (n=43) were isolated and prepared for constant pressure 
perfusion studies as previously published [2, 24-26]. Briefly, animals 
were injected i.p. with 10 mg/kg ketamine to induce anesthesia and 
with 5000 units heparin to prevent coagulation. Following decapitation 
and thoracotomy, hearts were removed and perfused with Krebs-
Ringer's buffer (KR) (in mM 138 Na+, 4.5 K+, 1.2 Mg2+, 2.5 Ca2+, 134 
Cl-, 15 HCO3-, 1.2 H2PO4-, 11.5 glucose, 2 pyruvate, 16 mannitol, 0.05 
EDTA and 5 U/L insulin) gassed with 3% CO2, 97% O2 at pH 7.4 and 
37°C. A saline filled balloon catheter attached to a transducer was 
used to measure left ventricular pressure (LVP). Diastolic LVP was set 
initially to zero in order to monitor any increase and an indicator of 
diastolic contracture, a marker of ischemic injury. Coronary flow was 
measured using an ultrasonic flowmeter (model T106X, Transonic 
Systems) placed directly into the aortic inflow line. Spontaneous heart 
rate was monitored using bipolar electrodes placed on the right atrial 
and ventricular walls. 
2.2. Protocols for isolated, perfused heart 
Given that IR injury is time dependent [27-29], we used an 
experimental protocol of 30 min of ischemia followed by 10 min 
reperfusion to assess changes in complex I. Once heart rate and LVP 
had stabilized each heart was subjected to one of the following six 
protocols: 60 min of control perfusion (TC) (n=8); 30 min global 
ischemia (I30) (n=8); 30 min global ischemia followed by 10 min of 
reperfusion (IR) (n=8); 10 μM Ran given 1 min prior to 30 min global 
ischemia (RanI30) (n=8); 10 μM Ran given 1 min before 30 min global 
ischemia followed by 10 min reperfusion (RanIR) (n=8), and 10 μM 
Ran given for 1 min followed by 40 min of KR perfusion (RanTC) 
(n=3). At the end of each experiment, some hearts were immediately 
immersed into liquid N2 for later assessment of changes in electron 
paramagnetic resonance (EPR) signals, or for later determination of 
cardiolipin integrity by high pressure liquid chromatography (HPLC); 
alternatively mitochondria were isolated, as described below, for 
western blotting, analysis of supercomplex assemblies, and 
assessment of complex I activity (NADH oxidation). 
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2.3. Isolation of mitochondria 
At the conclusion of each protocol, some hearts were 
immediately removed from the perfusion apparatus and mitochondria 
were isolated as previously described [30, 31]. In brief, ventricles 
were excised, placed in isolation buffer (in mM: 200 mannitol, 5 
KH2PO4, 5 MOPS, 1 EGTA, 0.1% BSA and 0.5 mg/ml butylated hydroxy 
toluene as an anti-oxidant (pH adjusted to 7.15 with KOH)), and 
minced into fine pieces. The suspension was homogenized for 30 s in 
2.5 ml isolation buffer containing 5 U/ml protease (Bacillus 
licheniformis, Sigma) and for another 1 min after adding 17 ml 
isolation buffer. The suspension was centrifuged at 8,000 g for 10 min. 
The pellet was re-suspended in 25 ml isolation buffer and centrifuged 
at 750 g for 10 min, the supernatant was centrifuged again at 8,000 g 
for 10 min, and the final pellet, enriched in mitochondria, was re-
suspended in 0.5 ml isolation buffer and stored at -80°C until further 
use. 
2.4. Assessment of mitochondrial complex I activity 
Mitochondria isolated as described above were centrifuged at 
10,000 g and the pellet was re-suspended and washed in hypotonic 
buffer containing 25 mM potassium phosphate buffer with 5 mM MgCl2 
at pH 7.2 by centrifugation at 10,000 g. After dilution to the 
appropriate concentration, mitochondria were subjected to three 
rounds of freeze-thaw cycles in the same hypotonic buffer. The 
fractured mitochondria were used for assay of dynamic respiratory 
complex I activity using a cuvette-based spectrophotometer (PTI- 
model QM-8, Photon Technology International). The 
spectrophotometer was configured for measuring transmittance and 
used specifically to derive the kinetic profile of complex I activity over 
time. 
Complex I activity was measured by monitoring the dynamic 
change in transmittance from oxidation of NADH to NAD+ at 340 nm in 
a pH 7.2 buffer containing 25 mM potassium phosphate buffer with 5 
mM MgCl2, 2 mM KCN, 2.5 mg/ml BSA, 0.13 mM NADH, and 65 μM 
ubiquinone (UQ10) in a total volume of 1 ml [32]. Briefly, after a 3 min 
baseline measurement, 5 μg of the mitochondrial lysate was added 
and transmittance was recorded continuously for another 5 min; this 
was followed by transmittance recorded for 3 min after the addition of 
2 μg rotenone to completely block complex I activity. The rate of 
transmittance after adding rotenone was subtracted from the initial 
rate of change in transmittance, due to addition of mitochondria, to 
obtain rotenone sensitive activity. The rates of enzyme activity of all 
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groups were normalized to citrate synthase activity to account for 
difference in active enzyme at the time of isolation. Rate of activity 
was calculated using the extinction coefficient of NADH, 6.81 mM-1 cm-
1 with slopes derived over the period between 200 and 260 s (first 
order rate kinetics) [32]. 
2.5. Histochemical staining of complex I 
The amount of total complex I and activity was also determined 
using histochemical staining. First, freshly isolated mitochondria were 
disrupted using the method of Schägger et al. [35]. Briefly, 400 μg of 
pelleted mitochondria was re-suspended in pH 7.0 buffer containing in 
mM: 50 NaCl, 50 imidazole/HCl, 2 6-aminohexanoic acid, and 1 EDTA. 
Next mitochondria were solubilized by adding dodecylmaltoside (2.5 
g/g) and digitonin (6.0 g/g), followed by incubation on ice for 10 min 
and centrifugation at 16,000 g for 30 min. Then the supernatant was 
retained and 5 μl of 50% glycerol was added. Gradient gels with a 4-
13% polyacrylamide gradient were used for separation of respiratory 
complexes using 25 mM imidazole anode buffer and 50 mM tricine, 7.5 
mM imidazole cathode buffer. Gels were then used for histochemical 
staining to assess mitochondrial complex I actvity, by incubating the 
gel in 5 mM Tris-HCl, pH 7.4, containing 0.5 mg/ml Nitro Blue 
Tetrazolium chloride (NBT) and 2.5 mg/ml NADH. Bands were visible 
after 5 min incubation. The gels were transferred into Tris-HCl at pH 
7.4 and scanned for densitometry. Individual band densities were 
normalized to their total respective lane Coomassie stain intensities. 
2.6. Determination of supercomplex assemblies 
Mitochondrial respiratory complexes are integrated into multi-
complex assemblies that can be detected using native gel 
electrophoresis [33, 34] with the use of mild detergents to solubilize 
the mitochondrial membranes while preserving both the functional and 
structural integrity of the complexes. Mitochondria were prepared as 
described for histochemical staining for complex I activity, except that 
6.0g/g digitonin, and no DDM, was used for solubilization of 
mitochondria and retaining supercomplex assemblies [36]. Proteins 
were then separated as described above in a 3-13% polyacrylamide 
gradient gel, and used for either Coomassie staining or histochemical 
staining of respiratory complexes. 
For Coomassie staining, gels were stained for 20 min in 0.2% 
Brilliant Blue G in methanol:acetic acid:water (MAW) (40:7:53 v/v), 
and later destained with MAW. After destaining, the gels were scanned 
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using a desktop scanner (CanoScan 8400F) and densitometry was 
performed using the ImageJ program (National Institutes of Health, 
Bethesda, MD). Respiratory complex I function was detected as in 
Section 2.5. Complex III and IV functions were determined by 
incubating the gels in 50 mM sodium phosphate buffer at pH 7.2 
containing 5 mM cytochrome c and 0.5 mg/ml diaminobenzidine [36]. 
Histochemical staining of complexes III and IV was performed to 
determine supercomplex components. The observed band intensities 
were normalized against total lane Coomassie stain intensities. The 
components of supercomplexes were further determined by 2nd 
dimension SDS-PAGE. Briefly, supercomplex bands positive for 
complexes I, III and IV were excised from the gel and incubated in 1% 
SDS and 1% β- mercaptoethanol for 1 hr at room temperature. The 
bands were then placed in lanes of a 10% polyacrylamide gel and 
electrophoresed in Tris-Glycine-SDS buffer for 1.5 hrs at 125V. The 
proteins were then transferred onto PVDF membranes and used for 
Western blots using a cocktail of antibodies (Invitrogen, CA) against 
the following proteins: complex I subunit ND6, complex II FeS subunit, 
complex III core 2,complex IV subunit I, and complex V subunit ∝. 
2.7. Western blot detection of complex I 
Complex I subunit NDUFA9 is an integral membrane subunit 
reported to be more prone to post translational modifications (PTM) 
than other subunits [37, 38]. Hence any change in levels of this 
subunit indicates compromised membrane integrity and possibly PTM 
of the subunit. Mitochondrial protein (50 μg) was solubilized in 
Laemmli buffer and resolved using sodium dodecyl sulphate- 
polyacrylamide gel electrophoresis (SDS-PAGE) as described by 
Laemmli [39] and transferred onto poly vinilidine difluoride 
membranes using Transblot System (Bio-Rad, Carlsbad, CA) in 50 mM 
tricine and 7.5 mM imidazole transfer buffer. Membranes were blocked 
with 10% non fat dry milk in Tris Buffered Saline- TBSt (25 mM Tris-
HCl at pH 7.5, 50 mM NaCl and 0.1% Tween 20) by incubating for 1 h 
followed by incubation in anti- NDUFA9 antibody (Invitrogen, CA) 
solution overnight at 4°C. After three washes with TBSt the membrane 
was incubated with an appropriate secondary antibody conjugated to 
horse-radish peroxidase for 3 h. After five washes with TBSt the 
membrane was incubated in enhanced chemiluminescence detection 
solution (ECL-Plus, GE-Amersham) and exposed to X-ray film for 
autoradiography. Equivalent protein loading was confirmed using an 
antibody against cytochrome c oxidase (complex IV) subunit 1 
(Invitrogen, CA) since complex IV is relatively more resistant to IR 
injury than is complex I at 10 min reperfusion [27-29]. 
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2.8. Acetylation of mitochondrial protein 
A common PTM is acetylation. Total mitochondrial protein 
acetylation was analyzed using Enzyme Linked Immuno Sorbent Assay 
(ELISA). Mitochondria, isolated as described above, were solubilized by 
suspension in phosphate buffered saline, pH 7.4, by the addition of 
0.5 % Tween-20. 20 μg of the lysed protein was suspended in 50 μl of 
sodium carbonate-bicarbonate buffer, pH 7.4 and coated overnight in a 
96 well plate. The wells were washed with PBS and blocked with 1% 
BSA. After three washes, anti-acetyl lysine antibody was added to 
each well. Following a three-hour incubation, the wells were washed 
again in PBS, and incubated with appropriate secondary antibody. 
Color development was achieved by the use of a solution containing o-
phenyline diamine, citric acid, and H2O2. The plate was scanned for 
changes in optical density at 490 nm [40]. 
2.9. Electron paramagnetic resonance 
An EPR system (Elexsys 580 Pulse EPR spectrometer, Bruker, 
Billerica, MA) was used to detect the transfer of e- through respiratory 
complexes I and II (succinate dehydrogenase) resulting from the 
successive oxidation/reduction of Fe in Fe-S clusters. Some treated or 
untreated isolated hearts (n=4 per group) were immediately 
transferred to liquid N2 at the end of the protocol and ground to a fine 
powder. The powder was transferred into quartz glass tubes which 
were stored at -80°C until analysis. EPR signals were obtained by 
scanning the samples in a high intensity magnetic field (3000-4000 G) 
at 10 Kelvin, 9.6 GHz, 5 mW microwave power and 5 G amplitude 
modulation. Each sample was scanned 9 times and spectra were 
averaged [41, 42]. Signal intensities were measured for g’s of 2.023 
(3Fe-4S attributed to cluster S3 of complex II, or to mitochondrial 
aconitase), 2.006 (attributed to semi-ubiquinone radical, UQ•), 1.94 
(2Fe-2S attributed to N1b of complex I, or to S1 of complex II), and 
1.89 (4Fe-4S attributed to N4 of complex I, or to the Rieske center of 
complex III [43]. 
2.10. Isolation and analysis of cardiolipin by HPLC 
The integrity of cardiolipin isolated from minced heart tissue was 
assessed using HPLC (System Gold, Beckman Coulter, Fullerton, CA). 
HPLC detects difference in molecular weight, and thus different 
species, by the change in mobility of individual molecules through the 
HPLC column. Lipids were extracted from hearts using a modified 
method of Hara et al. [44]. Briefly, hearts were removed from the 
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perfusion system after treatments and quickly frozen in liquid N2 and 
ground to a fine powder. Approximately 1 g of powdered tissue was 
added to 18 ml hexane:isopropanol (3:2) and mixed for 1 min. The 
suspension was filtered through Whatman no. 5 filter paper. The 
powdered tissue was washed twice with 2 ml hexane:isopropanol. 
Isolated lipids were then analyzed and estimated for cardiolipin 
content using thin layer chromatography (TLC). Briefly, 200 μl of each 
sample was loaded onto a Whatman silica gel-60 TLC plate and 
allowed to dry; 50 μg of purified bovine heart cardiolipin was used as 
the standard. Lipids were separated using chloroform:methanol:acetic 
acid:water (55:37.5:3:2) [45]. Bands were visualized by exposure to 
iodine vapors for 5 min. The ratio of band intensity for each group's 
cardiolipin was estimated and total lipids in each fraction were 
calculated. Appropriate amount of lipids equivalent to 200 μg of 
cardiolipin was dried under N2 gas and resuspended in 20 μl 
hexane:isopropanol (3:2) and then injected into the HPLC. HPLC 
analysis was performed using the method of Barcelo-Coblijn et al. [45] 
at 208 nm. 
2.11. Statistical evaluation of data 
For the intact heart studies, measurements for each group were 
compared at baseline, during the brief treatment with or without Ran 
before ischemia, at 30 min ischemia, and at 10 min reperfusion. For all 
other studies, measurements for each group were measured at the 
end of the protocol. All data are expressed as mean ± SEM. Between 
groups and within group individual values were subject to two-way 
analysis of variance to determine overall significance. If F values were 
significant (P < 0.05), post hoc comparisons of means tests (Student-
Newman-Keuls) were used to compare the groups within each subset. 
In mitochondrial studies, statistical analysis was performed similarly. 
Differences between means were considered significant when P < 0.05 
(two-tailed). 
3. Results 
3.1. Spectrophotometric determination of complex I 
activity 
Representative kinetic traces of complex I activity, monitored in 
a spectrophotometer as the rate of oxidation of NADH to NAD+ in the 
presence of UQ10, illustrate differences dependent on the treatment 
(Fig. 1A). In summarized data from 4 hearts from each of the 5 
experimental groups (Fig. 1B) controls (TC) exhibited a NADH 
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oxidation rate of 122±5 nmol/min/mg protein with a large decrease in 
oxidation rate after I30 to 49±8 nmol/min/mg, but partial restoration 
to 106±1 nmol/min/mg in the RanI30 group. Similarly, there was a 
large decrease in complex I activity after IR to 70±4 nmol/min/mg, 
which was completely restored to 123±7 nmol/min/mg in the RanIR 
group. No changes in complex I activity were observed in the RanTC 
group (data not shown). To determine if Ran directly alters 
mitochondrial complex I activity in fractured mitochondria, in 
preliminary experiments Ran was added to freeze-thaw fractured 
mitochondria from the TC, I30 and IR groups, followed by 
measurement of complex I activity; the result was a slight but 
insignificant decrease in activity (data not shown). 
 
 
 
Fig. 1 A: Representative spectrophotometric assay of mitochondrial complex I 
activity during cardiac ischemia reperfusion depicting the time points of addition of 
substrate, enzyme and the inhibitor. B: Summary data shows ischemia alone reduced 
the activity of the enzyme, which was restored by treatment with ranolazine. 
Reperfusion itself corrected the decrease in activity, but this was not as pronounced as 
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with ranolazine (Ran) on reperfusion. Note that the activities depicted in B have been 
corrected for rotenone sensitivity and normalized to citrate synthase levels. * indicates 
p<0.05 for I30/IR vs. TC; # indicates p<0.05 for RanI30/RanIR vs. I30/IR 
3.2. Histochemical staining for complex I function in gel 
A representative gel (Fig. 2, upper panel) for NBT-
oxidoreductase activity, reflecting complex I function with or without 
IR and Ran, illustrates decreased band density after I30 and IR but a 
higher band density after RanI30. Summary data (Fig. 2, lower panel) 
showed that band density decreased after I30 (87±3%) and IR 
(87±5%) compared to the normalized TC group (100%). Ran 
treatment before ischemia resulted in a significantly higher band 
density for RanI30 (95±4%) vs. I30 alone, whereas band density for 
RanIR (91±4%) was not significantly greater than that for IR alone. 
The observed band densities were normalized to the total lane 
intensities. 
 
Fig. 2 Upper panel: Representative histochemical gel staining of complex I activity, 
measured as NBT-oxidoreductase, during cardiac ischemia reperfusion. Lower panel: 
Summary data shows ischemia alone resulted in lower staining than in time controls 
and reperfusion. Ran treatment increased staining, indicating improved complex I 
function. * indicates p<0.05 for I30/IR vs. TC; # indicates p<0.05 for RanI30/RanIR 
vs. I30/IR 
3.3. Supercomplex assemblies detected by native gels 
A representative image of a native gel (Fig. 3, panel A) stained 
by Coomassie Brilliant Blue illustrates supercomplexes- SC1 and SC2 
comprised of complexes I, III and IV as identified by histochemical 
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staining for complex I (panel B) and III and IV (panel C), and 
respiratory complexes after 2D electrophoresis detected by Western 
blot using antibodies against the indicated subunits (panel D). The two 
supercomplexes presumably are composed of multiple copies of 
respiratory complexes. Summary data of supercomplex assemblies 
from Coomassie stained gels (Fig. 3E) showed that band intensity for 
the supercomplex SC1 (TC =100%) was lower in I30 (86±1 %), IR 
(88±1%) and RanI30 (87±2%). Ranolazine treatment improved the 
band intensity of SC1 following IR (96±1%). Band intensity for 
supercomplex SC2 showed similar results. Compared to TC (100%), 
there was a significant decrease in band intensity in I30 (77±5%) and 
IR (85±2%). Ranolazine treatment improved band intensity following 
I30 (RanI30=93±1%) and IR (RanIR=95±5%). Complex I was not 
found to associate further with complexes II and V to form other 
supercomplexes (data not shown). The observed band densities were 
normalized to the total lane intensities. 
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Fig. 3 Determination of supercomplex assemblies using native PAGE. Panel A: 
Coomassie stained gel after native PAGE. SC1 and SC2 indicate supercomplexes 
composed of complexes I, III and IV, with varying copies of each complex. 
Components of supercomplex determined by histochemical staining for complex I 
(panel B), complexes III and IV (panel C) and by Western blot analysis of SC1 and 
SC2 against respiratory complex subunits (panel D). Summary data of supercomplex 
assemblies from Coomassie stained gels (panel E) shows reduction in supercomplex 
assemblies following ischemia and reperfusion, and restoration by ranolazine 
treatment. * indicates p<0.05 for I30/IR vs. TC; # indicates p<0.05 for RanI30/RanIR 
vs. I30/IR 
3.4. Determination of integrity of complex I 
subunit NDUFA9 by Western blots 
A representative blot for the complex I subunit NDUFA9 (Fig. 4, 
upper panel) from hearts subjected to IR ± Ran illustrates decreased 
intensity after I30 and restoration after RanI30 and RanIR. Complex IV 
subunit I was used as the loading control. Summary data (Fig. 4, lower 
panel) showed that compared to TC (100%) the anti-NDUFA9 immune 
reactive band intensity was significantly lower after I30 (84±9%) but 
was restored after RanI30 (109±7%). Band densities for IR (101±4%) 
and RanIR (112±7%) groups were not different from the TC group. 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
[Citation: Journal/Monograph Title, Vol. XX, No. X (yyyy): pg. XX-XX. DOI. This article is © [Publisher’s Name] and 
permission has been granted for this version to appear in e-Publications@Marquette. [Publisher] does not grant 
permission for this article to be further copied/distributed or hosted elsewhere without the express permission from 
[Publisher].] 
14 
 
 
Fig. 4 Upper panel: Representative western blot detection of complex I subunit 
NDUFA9 during cardiac ischemia reperfusion. Lower panel: Summary data shows 
that ischemia reduced the amount of detectable subunit, indicating a loss of protein or 
protein damage. Both reperfusion and Ran treatment during ischemia restored protein 
levels to time control levels. * indicates p<0.05 for I30/IR vs. TC; # indicates p<0.05 
for RanI30/RanIR vs. I30/IR 
3.5. Analysis of acetylation of mitochondrial proteins 
using ELISA 
The optical density for acetylated mitochondrial proteins, as 
detected by ELISA, showed an overall decrease in all groups compared 
to TC (76±4.9 arb. units) (data not represented graphically). I30 
showed the least acetylation (41.7±3.1 arb. units), whereas IR 
partially restored the acetylation (57.8±4.6 arb. units). Treatment with 
Ran partially restored acetylation in both groups (Ran I30 = 56.5±2.7 
arb. units; RanIR = 59.8±2.3 arb. units). Values for each treatment 
group were significantly lower than the TC group, and there was a 
statistically significant difference (p<0.05) between I30 and RanI30, 
but not between IR and RanIR groups. 
3.6. Electron transfer in Fe-S clusters by electron 
paramagnetic resonance 
Averaged peak intensities (4 hearts per group) of Fe-S 
resonance signals (in arb. units) showed differences in peak signals 
dependent on the treatments (Fig 5A). The g=2.023 signal was 
assigned to S3, the 3Fe-4S cluster of complex II, or to mitochondrial 
aconitase, g=2.006 to the semi-ubiquinone radical (UQ•), g=1.94 to 
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cluster N1b of complex I, or to cluster SI of complex II, and g=1.89 to 
cluster N4 of complex I, or to the Rieske center of complex III. 
Summary data (Fig. 5B) showed that compared to TC (3.1±1.4 arb. 
units), neither I30 (2.7±0.8) nor IR (4.2±0.6) significantly altered the 
g=2.023 signal. However, Ran treatment reduced the g=2.023 signal 
further after RanI30 (1.6±0.4), but not after RanIR (4.2±1.0). There 
was a significant increase in the g=2.006 radical after I30 
(1.49±0.07), which was lower in TC (0.87±0.09) and after IR 
(1.06±0.03). Ran treatment also reduced the g=2.006 signal (RanI30 
= 1.29±0.09; RanIR = 1.02±0.04). There was also a significant 
increase in signals pertaining to g=1.94 and 1.89 during ischemia, 
which returned to TC levels after reperfusion. The contribution at 
g=1.94 for N4 was verified by the changes noted at g=1.89; i.e. the 
contribution of N1b and S1 can be estimated after evaluating the 
contribution of N4. The signal at g=1.94, contributed by N3, was small 
as estimated by the weak signal at g=1.86, the low field g-value for 
the signal from N3. Similarly the contribution to the signal at g=1.92 
from N2 was weak as determined by the absence of signal from the 
low field g-value for N2 at 2.05. 
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Fig. 5 A: Representative traces of EPR signals during cardiac ischemia reperfusion 
denoting changes in three mitochondrial Fe-S clusters and semiubiquinone. B: 
Summary data shows the changes in spectral magnitudes of the Fe-S clusters and 
semiubiquinone. Ischemia increased electron transfer within complex I and 
semiubiquinone; this was reversed on reperfusion. Ran had a small effect to decrease 
electron transfer during reperfusion. I, II, III = respiratory complexes; N and Rieske = 
FeS clusters. * indicates p<0.05 for I30/IR vs. TC; # indicates p<0.05 for 
RanI30/RanIR vs. I30/IR 
3.7. Determination of cardiolipin integrity by HPLC 
Representative HPLC traces of cardiolipin integrity were different 
depending on treatment (Fig. 6A). Compared to the cardiolipin 
standard TC (93±2 arb. units), there were significant decreases in the 
areas under the curves in I30 (56±21 arb. units) and more so in IR 
(32±12 arb. units) groups, reflective of damaged cardiolipin. In 
summary data (Fig. 6B) the RanI30 group (49±15 arb. units) showed 
no improvement over the I30 group alone, but the RanIR (69±8 arb. 
units) group showed a larger area under the peak that is reflective of 
less fragmented cardiolipin. The number of peaks as detected by HPLC 
was also higher (reflecting more fragmented species) in I30 and IR 
groups than in RanI30 and RanIR groups, respectively (Fig. 6A). 
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Fig. 6 A: Representative traces of cardiolipin integrity by HPLC analysis during 
cardiac ischemia reperfusion. B: Summary data shows that ischemia alone reduced 
the area under the major peak of cardiolipin, and reperfusion decreased it further. The 
additional peaks seen in the spectra could be modified/breakdown products of 
cardiolipin. Treatment with ranolazine restored peak heights and also decreased the 
number of peaks, indicating that ranolazine treatment preserves cardiolipin. * 
indicates p<0.05 for I30/IR vs. TC; # indicates p<0.05 for RanI30/RanIR vs. I30/IR 
3.8. Improved cardiac function after IR injury with 
ranolazine 
Heart rate, coronary flow, diastolic LVP, and developed (systolic-
diastolic) LVP remained unchanged during continuous perfusion of 
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hearts for 60 min (TC, data not displayed) after which time hearts 
were harvested for examination of complex I function using the 
methods described above. At the end of 30 min no flow global 
ischemia, there was no heart beat and diastolic LVP was elevated 
(Table 1); after 10 min reperfusion heart rate and coronary flow were 
similar to those of the TC in all IR groups. On the other hand, diastolic 
LVP was more elevated in the IR group than in the RanIR group and 
developed LVP was more depressed in the IR group than in the RanIR 
group. These data indicate that Ran had a protective effect on 
reducing contracture during ischemia and on increasing contractile 
function on reperfusion. These protective effects were associated with 
improvements in several assays of complex I function and the integrity 
of its support structure, cardiolipin. 
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4. Discussion 
4.1. Summary of findings 
Complex I is a major source and target of ROS during IR [4, 28] 
and excess ROS is a major determinant of poor return of cardiac 
function after IR injury [2, 25]. For that reason we used several 
experimental tools to search for deleterious biochemical and 
biophysical changes in respiratory complex I function and structural 
integrity in hearts subjected to 30 min ischemia alone, or to ischemia 
plus 10 min reperfusion. Ran, which is reported to have cardio-
protective effects [11, 12, 14, 15] by switching substrate preference, 
among other proposed effects [16], was examined for its potential to 
attenuate damage to complex I and to improve cardiac function when 
present during ischemia. 
We found that ischemia alone a) reduced the rate of NADH 
oxidation, b) reduced protein acetylation, c) decreased complex I 
function, d) reduced supercomplex assembly, e) decreased the 
detection of a complex I subunit, f) increased the reduced state 
several fold in three distinct Fe-S clusters in complex I and/or complex 
II [2Fe-2S in N1b and/or S1 and the 4Fe-4S cluster N4, and in 
complex I N4 and/or Rieske center in complex III], increased the 
signal at 2.006 (UQ•) but did not alter the signal at 2.023 [S3 in 
complex II and/or aconitase] and, g) reduced the structural integrity 
of cardiolipin, a supporting structure for mitochondrial complexes. 
Compared to ischemia alone, treatment with Ran during ischemia 
resulted in full or partial restoration of: a) the rate of NADH oxidation, 
b) the acetylation of mitochondrial proteins, c) the detection of 
complex I subunit, and d) the supercomplex assembly. 
During the short 10 min reperfusion period, complex I 
dysfunction persisted, acetylation levels remained lower, and 
cardiolipin showed greater disintegration. Because the expression 
levels of respiratory complex I subunits are not likely to change given 
the short time period of our protocols, any reduction in complex I 
subunit band intensity probably reflects compromised integrity of the 
subunit's structure. The reduction in NADH oxidation rate with 
reperfusion alone was reversed and cardiolipin integrity was improved 
by Ran treatment. Electron transfer through N1b of complex I and/or 
SI of complex II was improved by Ran on reperfusion and through N4 
of complex I or the Rieske center of complex III. Each of these 
changes observed after Ran treatment was associated with improved 
diastolic LVP during ischemia and improved contractile function during 
reperfusion. However, Ran did not alter complex I activity when 
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applied directly to fragmented mitochondria in either the TC, I30, or IR 
groups. 
Our study supports our alternative hypothesis that Ran 
treatment indirectly leads to partial protection of mitochondria, as 
shown in part, by improved complex I activity, restored e- transfer 
through some Fe-S clusters, and retained supercomplex assembly and 
cardiolipin integrity. This range of protection implies that Ran is not 
likely to have a direct molecular interaction with complex I, which is 
substantiated by our preliminary finding that Ran had no effect on 
complex I activity when added directly to fractured mitochondria. 
Hence we conclude that Ran acts indirectly at another site to reduce 
damage to mitochondrial structure. We propose that by maintaining 
complex I e- flow and preserving the supercomplex assemblies, the 
tendency for electron leak and subsequent generation of O2•- is 
reduced. This notion is supported by our recent observation [18] that 
by lowering ROS emission with reduced cytosolic and m[Ca2+] loading, 
Ran indiscriminately reduces oxidative damage to complex I and to its 
supporting structures (among other mitochondrial and cytosolic 
molecules). Our comprehensive examination of complex I function 
during IR injury demonstrates the extent of structural and functional 
damage to complex I and the impact of a non-mitochondrial-targeted 
drug to indirectly protect mitochondrial function, likely by reducing 
ROS emission. 
4.2. ROS and damage to respiratory complexes during 
cardiac injury 
Superoxide radicals (O2•-) are produced in small amounts in 
mitochondria under O2 and substrate replete conditions, but the 
balance between O2•- generation and free radical scavenging, (ROS 
emission), is altered in high oxidative conditions such as IR injury [1, 
22, 46, 47]. These O2•- radicals and their downstream products attack 
all types of cellular macro molecules, i.e. proteins, lipids, 
carbohydrates, and D(R)NA, thereby altering their structure and 
function [48, 49]. Although all major biomolecules are susceptible to 
oxidative damage, the extent of this damage is dependent on the 
molecular structure, the length of exposure to ROS, the concentration 
and kind of ROS, and the capacity of ROS scavengers available. 
Respiratory complexes differ in their susceptibility to IR injury. 
Complexes I and III are believed to be more susceptible to IR injury 
than complexes II, IV, and V [22]. A useful kinetic test for an effect of 
Ran to protect respiratory complex I against IR injury is the measure 
of catalytic conversion rate of NADH to NAD+ in complex I during IR. 
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Although respiratory complexes I and III are reported to be a major 
source of O2•- generation [1, 3, 50, 51], many studies have implicated 
complex I to also be the most susceptible of the respiratory complexes 
to ischemic damage [4, 52]. Complex I is also a major site of e- leak 
during IR; this is likely to drive e- transfer backward through complex I 
toward the NADH binding site [2, 53, 54]. Indeed, in our collateral 
histochemical and kinetic experiments we found that complex I 
function was attenuated; this is consistent with the increased 
(backward) e- transfer in complex I and the decreased (forward) e- 
transfer in complex II [22, 55]. 
Interventions to limit backward e- transfer from complex II into 
complex I may be helpful in attenuating ROS release [2, 53, 56]. 
Indeed, we [56] showed previously that amobarbital, a complex I 
blocker at the rotenone site, itself slightly enhanced generation of O2•- 
before ischemia but attenuated O2•- emission during IR [2]. Other 
modulators of complex I are also known to have protective effects 
against IR injury [52]. The decreased rate of NADH oxidation in 
ischemic hearts, compared to reperfused hearts, might also be due to 
a lack of the e- acceptor O2. When reperfusion begins there is an 
abrupt availability of O2, and hence a higher rate of respiratory chain 
activity. In support of this, we found faster respiratory complex I 
activity in Ran -treated hearts than in the untreated ischemia and IR 
groups 
4.3. Mechanism of mitochondrial protection by 
ranolazine during cardiac IR injury 
Ranolazine is a clinically useful anti-anginal drug [15, 57] that 
was found originally to block the late Na+ current that occurs with 
ischemia [11, 58-60]. But others have reported that Ran induces a 
switch from the usual substrate preference from fatty acids to glucose, 
and that it partially blocks complex I at an unconfirmed site, 
particularly in uncoupled mitochondria [21]. If Ran were indeed a 
partial complex I blocker in vivo as Wyatt et al. [21] reported in in 
vitro isolated mitochondrial experiments, this might contribute to 
preserving its structure and function during IR injury as we found. But 
it is unlikely that Ran penetrates membranes effectively due to its 
hydrophilic structure. It is conceivable that a fat soluble metabolite of 
Ran is a direct mitochondrial protective drug, but this will require 
direct evidence of a metabolite with actions on complexes and other 
mitochondrial targets. Because we found that Ran had no direct effects 
on mitochondrial function when applied directly to isolated, energized 
mitochondria [18], or to fractured mitochondria, we believe it is 
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unlikely to directly target complex I or any other mitochondrial protein 
and its supporting structures. 
During ischemia there is an increase in cytosolic [Na+] due to 
failure of the Na+/K+ ATPase pump and an increase in toxic 
intermediates [60]. This triggers NCE, which results in increased cell 
Ca2+ loading, and consequently, m[Ca2+] loading which may lead to 
mitochondrial oxidative damage by “Ca2+-induced ROS release” [46, 
61]. Increased m[Ca2+] contributes to an increase in ROS emission 
under certain circumstances, either by increasing the rate of O2•- 
generation or by reducing the rate of ROS scavenging [17, 61, 62]. 
Therefore we postulated that Ran induces its protective effect by 
reducing NCE in the cytosolic compartment to reduce Ca2+ loading, and 
by extension, to mitigate m[Ca2+] loading. Our conclusion derives from 
the principal earlier finding that Ran is a late Na+ channel current 
blocker [11, 58-60], and our report that Ran reduces m[Ca2+] overload 
and ROS emission during late ischemia and reperfusion [18]. This 
decrease in ROS may or may not be a direct consequence of an 
improved electron transport chain activity or reduced m[Ca2+] 
overload. However, Song et al. [63] reported that Ran attenuated H2O2 
-induced cytosolic Ca2+ overload and cardiac contractile dysfunction 
suggesting that “ROS induced Ca2+ loading” can be attenuated by Ran. 
The oxidative stress that occurs in ischemia is known to activate 
deacetylases [64, 65], which cause a decrease in lysine acetylation. 
Deacetylation can disturb the secondary and tertiary associations 
among proteins and/or their subunits. Hence it is possible that by 
preserving acetylation, a reversible PTM, this might help preserve the 
integrity of mitochondrial proteins. Ran treatment attenuated the 
lysine deacetylation of mitochondrial proteins during ischemia. If Ran 
could access the mitochondrial matrix, it might interfere with the 
action of deacetylases to protect the proteins but there is no direct 
evidence for this. 
4.3. Electron transfer in complex I and protective effect 
of ranolazine during cardiac IR injury 
Changes in EPR spectra can occur due to many factors, 
including but not limited to: a loss of one or more Fe-S clusters, a 
saturated oxidation or reduction potential, and proximity of 
neighboring clusters. Complex I subunits with their Fe-S clusters 
mediate single e- transfer so any damage to these subunits or Fe-S 
clusters will cause disrupted e- transfer. Once an e- enters the Fe-S 
cluster chain, its further movement is affected by the redox states of 
the following Fe-S clusters [6, 66]. From FMN one e- enters a transport 
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chain consisting of one binuclear and the six tetranuclear Fe-S clusters 
leading (during forward e- transfer) to the Q10 binding site (FMN → 
N3→N1b–N4–N5–N6a–N6b→N2→UQ•→Q10) [73] and ultimately to 
complex III. In our study, we observed no significant change in the 
g=2.023 signal representing the 3Fe-4S cluster, S3, of complex II with 
IR. In contrast, results of Myers et al. [42] reported a decrease in the 
aconitase signal (with the same g value) following oxidative stress with 
chromium radicals. There was a significant increase in the amount of 
the EPR detectable UQ• radical during ischemia, and this was reduced 
by reperfusion as well as by Ran treatment. It should be noted 
however, that UQ• is one of the several free radicals generated during 
ischemia, so this is not representative of the total oxidative stress in 
the tissue. 
In contrast to S3 of complex II, there were significant increases 
in the signal intensities for g=1.94 and 1.89 during ischemia that 
decreased again on reperfusion; this could represent reverse e- 
transfer during ischemia within complex I. It is difficult to ascertain the 
exact source of this signal because it can emanate from cluster N1b of 
complex I or SI of complex II. Although other clusters like the 4Fe-4S 
and N3 have a g-value close to 1.94 (1.93 for N3) the complementary 
peak (2.04 for N3) is too weak to detect, implying there is little 
contribution of signal from N3 at 1.93. Thus we attribute the 1.94 
signal to N1b and/or S1. 
Reverse e- transfer is believed to occur in the respiratory chain 
during ischemia, particularly within complex I [54]. Our results support 
this assumption. It is plausible from the EPR spectra of N1b (g=1.94) 
and N4 (g=1.89) clusters that ischemia can cause a severe back up of 
e- to cause reverse e- transfer back in complex I. Reperfusion 
appeared to largely correct this e- back up, whereas Ran did not affect 
signal intensity during ischemia, but increased it on reperfusion. The 
reason for this is unclear. Similarly, we observed an increase in signal 
intensity for g=1.89 during ischemia. Again, this signal can be 
attributed to either cluster N4 of complex I or the Rieske center of 
complex III; however, since most of this signal was generated by the 
N4 cluster (as noticed after spectral splitting at higher resolution), we 
conclude that the observed changes were due to cluster N4 and not to 
the Rieske center. 
The signal at g=2.023, assigned to the oxidized state of the 
3Fe-4S, S3 cluster in complex II decreased with ischemia and fell even 
more during 30 min ischemia with Ran, but recovered during 
reperfusion with or without Ran. We attribute the decrease in the 
2.023 signal to greater e- flow through complex II, thus reducing the 
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S3 center. This complements the suggestion that there is a reverse e- 
transfer during ischemia. 
4.4. Cardiolipin integrity and protective effect of 
ranolazine during cardiac injury 
Cardiolipin, a highly unsaturated fatty acid molecule, is prone to 
ROS attack with the most commonly encountered changes being lipid 
peroxidation and carbon chain breakdown [49]. The qualitative 
mobility of cardiolipin was assessed using HPLC by a change in area 
under the peak, compared to the cardiolipin standard, and by the 
appearance of secondary peaks with different retention times; these 
changes represent distortion of cardiolipin. Moreover, cardiolipin has a 
high content of oxidatively sensitive linoleic acid, a phospholipid 
unique to mitochondria. Its location in the IMM makes it extremely 
susceptible to oxidative damage by ROS, whether acutely as in IR 
injury or chronically as in aging [8, 9]. Cardiolipin is necessary not 
only for the assembly of each respiratory complex and the 
supercomplexes, but also for the proper functioning of respiratory 
complexes and for that matter an efficient e- transfer. Thus any 
fragmentation or damage to cardiolipin structure reflects on the 
performance of the respiratory complexes [4, 5, 10]. Indeed, in a pilot 
study, analysis of the complex I subunit NDUFS3, which is in the 
peripheral arm of complex I [67] showed no changes in Western blot 
band intensity with and without IR and with and without treatment 
with Ran (data not shown), compared to the decrease in band 
intensity of NDUFA9, which is a membrane integral subunit. This 
shows the importance of the integrity of cardiolipin on maintaining 
complex I structure and function. 
Ran is also reported to partially inhibit fatty acid oxidation [21] 
and to stimulate glucose oxidation in hearts during normoxia, 
ischemia, and IR [20, 68]. Thus Ran may also act as a metabolic 
modulator [19, 20] that promotes more efficient use of O2 and 
substrates. A reduction in ROS emission would likely reduce oxidative 
damage to cardiolipin, as suggested by our HPLC experiments, in 
which Ran -treated hearts exhibited a partial restoration toward the 
control cardiolipin HPLC spectra. Our data showing restoration of 
cardiolipin integrity, along with improvements in complex I structure 
and activity in the Ran treated hearts, are consistent with another 
study showing that restoration of cardiolipin content in mitochondria 
can improve complex I activity [4]. 
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4.5. Conclusions 
Protection of hearts against IR injury by Ran is associated with 
mitochondrial protection. Although Ran exerts a protective effect on 
complex I and its supporting structures, it is doubtful from our study 
that Ran mediates its protection by directly interacting with complex I, 
given our finding that Ran had no direct effect on complex I activity, or 
on any other mitochondrial function we measured in intact or 
fragmented mitochondria. The reversal or attenuation of complex I 
dysfunction, albeit indirect, by Ran points out the importance of 
complex I integrity and function as important factors in restoring 
cardiac function. Moreover, given the effects we and others observed, 
Ran appears to protect hearts in various ways, including but not 
limited to blocking the late Na+ current. Concomitant decreases in 
m[Ca2+] overload and ROS emission, induced by Ran, are the probable 
factors that lead to preservation of cardiolipin, maintaining 
supercomplex structure and less backward e- transfer through the Fe-S 
clusters of complex I, thereby improving its efficiency in function and 
NADH oxidizing capability. Nevertheless, our study emphasizes the 
extent of injury to complex I and other mitochondrial structures, and 
expresses the importance of understanding the mechanisms of 
compounds to protect mitochondria during cardiac IR injury. 
Highlights 
 Mitochondrial complex I is a major target of cardiac 
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 A cardio-protective drug, ranolazine, was found to indirectly 
reduce complex I damage. 
 Cardiac function after IR injury can be improved by indirectly 
reducing complex I dysfunction. 
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